Clinical Trial

Spinal Cord Stimulation for Refractory Pain Randomized Controlled Trial: the PAcStim RCT

Study acronym: PAcStim
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Neuropathic pain affects 6-10% of the global population and is poorly managed - current drug treatments succeed in only \~25% of patients. Spinal cord stimulation (SCS) modulates pain by electrically stimulating spinal dorsal column fibres. The newer paresthesia-free mode (PF-SCS, 500-10,000 Hz) appears more effective and tolerable than traditional paresthesia-based SCS, with superior outcomes shown in the SENZA-RCT. All promising PF-SCS studies have been unblinded, making them susceptible to placebo effects. The one blinded RCT that exists had significant methodological flaws (no washout period, single baseline measurement) that biased results toward the null. A blinded, multi-centre, crossover RCT in 90 patients comparing 6 weeks of active PF-SCS vs. 6 weeks of placebo stimulation, with a 2-week washout in between - designed to correct the flaws of the prior trial and definitively establish whether PF-SCS works beyond placebo.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12-01 -> 2027-06-01 2026-06-09
minor Completion pushed: 2027-04-01 -> 2027-12-01 2026-06-09
Trial Details
NCT Number NCT07468591
Lead Sponsor University Health Network, Toronto
Conditions Chronic Pain Syndrome
Enrollment 90 participants
Start Date 2026-07-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08